ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    NEXT STORY
    Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
    PREV STORY
    Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018

    The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of ...

    author_avatar
    NASDAQ Market News

    MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns

    author_avatar
    NASDAQ Market News

    Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results

    author_avatar
    NASDAQ Market News